Stenabolic SR-9009
SR9009 Also known as Stenabolic, has been studied in mice and has been shown to increase walking speed, reduce obesity levels and stimulate mitochondrial production, improving muscle mass and metabolism.
Although often associated with SARMS, SR-9009 acts in different pathways than other SARMs and is actually a nuclear receptor reverse viral erythroblastosis oncogene product alpha, agonist or a Rev-ErbA agonist, a protein found in the liver, skeletal muscles and brain, and it is best known for influencing the circadian rhythm.
SR-9009 and Weight Loss
In a study conducted by Solt et. Al, mice were supplemented with SR-9009 or saline injection twice daily while fed a high-fat diet (60% fat and 20% carbohydrates) to see whether or not SR-9009 was able to lose weight in a diet-induced obesity cases (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343186/).
It was found that as a result of the stress of twice-daily injection, both mice receiving SR-9009 and the inert placebo lost body fat, but the mice receiving injections of SR-9009 lost 60% more fat than the mice receiving injections. of a saline solution. In addition to significant fat loss, mice injected with SR-9009 were also reported to have a 12% decrease in plasma triglycerides, a 47% decrease in total cholesterol, a 19% decrease in plasma glucose levels, an 80% decrease in leptin, and a 72% decrease in inflammatory cytokines (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343186/).
SR-9009 and bone density
In an interesting study conducted by Song et. Already, 12-week-old female mice were housed in a research lab and kept on a strict 12-hour light-and-dark schedule and given free food and water. From there, 40 mice were divided into groups and given either a full oophorectomy or sham surgery. In mice that had undergone sham surgery, they were anesthetized and their ovaries were briefly touched with forceps, but not removed. After the procedure, mice were injected with a dose of 30, 50, or 100 mg/kg SR-9009 (http://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201600825RRR).
Overall, the results of this study showed that supplementation with SR-9009 inhibited the differentiation of osteoclast formation in mice, indicating that there was less bone breakdown after supplementation. In addition, in the female mice that underwent oophorectomy to mimic postmenopausal bone breakdown, SR-9009 supplementation was found to lead to a greater number of bone trabeculae in the femur and tibia. In addition, bone volume and tissue were found to be increased by a factor of 1,550, 1,701 or 1,601 when administered at doses of 30, 50 or 100 mg/kg SR-9009, respectively (https://faseb.onlinelibrary.wiley.com/doi/ full/10.1096/fj.201600825RRR).
Concentration
20 mg / ml.
DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or domestic use. Familiarize yourself with our DISCLAIMER before you order.
Included is a precision pipette marked per 0.2 ml!
Shake well before use.
data sheet
SR9009 - Oplossing, 7600 mg (20 mg / ml)
Application |
A potent agonist of Rev-ErbA |
|
CAS |
|
|
molar massa |
437.94 g/mol |
|
Chemical Formula |
C20H24ClN3O4S |
|
IUPAC name |
|
|
Synonyms |
Andarine, Andarin, S-4, S-40503, GTx-007 |
|
Bulletin |
room temperature |
|
Solubility |
Soluble in ethanol, DMSO. Slow degradation in PEG400, PPG |
|
Organoleptic profile |
Clear liquid |
|
Physical form |
Solution in PPG and DMSO |
|
Specification |
20mg/mL ±5% |
|
Requirements |
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or domestic use. Please familiarize yourself with our terms and conditions & disclaimer before ordering. |